The Swedish real-world study at AAIC 2026 tested how blood results change diagnosis for people with memory symptoms. For younger-onset families, the key interpretation questions are what a positive, intermediate, or negative result means and what care step follows. Younger-onset Alzheimer's means symptoms starting before age 65. The study included 1,310 patients with mild cognitive impairment or dementia and 165 primary and specialty physicians, led by Lund University neurologist Sebastian Palmqvist, according to the Alzheimer's Association release.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the test measure?
- How accurate were doctors after seeing results?
- What do positive, intermediate, and negative mean?
- What should younger-onset families ask next?
What did the test measure?
The studied blood test measures amyloid-beta and phosphorylated tau, abnormal brain proteins linked to Alzheimer's disease. These proteins can build up years before severe memory loss.
Reporting identified the approach as a PrecivityAD2-type test measuring phosphorylated tau-217 and amyloid-beta ratios in symptomatic patients, according to the Medical Daily report. It does not measure memory itself. It estimates the likelihood of amyloid plaques tied to Alzheimer's.
How accurate were doctors after seeing results?
After seeing blood results, primary-care physicians diagnosed Alzheimer's correctly 93% of the time, up from 65% before, nearly matching dementia specialists at 94%, according to the NeurologyLive summary. That gain matters for younger adults who often wait longer for answers.
Physicians changed diagnoses in about one-third of patients. They changed future care or examination plans for more than half.
What do positive, intermediate, and negative mean?
PrecivityAD2 combines two ratios into an Amyloid Probability Score 2 from 0 to 100. Scores fall into negative, intermediate, or positive groups. A negative result was especially useful for ruling out Alzheimer's in primary care.
A positive result is not a stand-alone diagnosis and needs clinical evaluation with possible PET scan or spinal-fluid confirmation. An intermediate result means the risk is unclear. For a parent in their 40s or 50s, that often means watchful follow-up, repeat testing, or specialist referral rather than immediate treatment decisions.
What should younger-onset families ask next?
Start with symptoms, age, and test purpose. The FDA cleared PrecivityAD2 on Aug.
20, 2026 to aid amyloid-plaque evaluation in adults age 40 and older with signs of cognitive impairment, according to the WashU Medicine announcement. Bring a symptom timeline, work changes, and family history to the visit. Useful questions include: Ask for the exact score group and next care plan in writing.
- Does this result rule Alzheimer's in or out for this person?
- Is an intermediate score reason for referral, imaging, or repeat testing?
- What other causes were checked, such as sleep, mood, medication, or thyroid issues?
You Might Also Like
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Result Interpretation Questions for Younger-Onset Alzheimer’s Families
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Changed and What Comes Next for Primary Care Patients
- The $781 Billion Dementia Economic Estimate in the 2026 NIA Report: What the Report Establishes and Leaves Unanswered for Spouses and Partners
